Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma : Outcome of Innate Pharma's Annual General Meeting (Form 6-K)

05/28/2021 | 04:07pm EDT

Outcome of Innate Pharma's Annual General Meeting

MARSEILLE, France, May 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) ('Innate' or the 'Company') announced the voting results of its shareholders at the Annual General Meeting ('AGM'), which took place on May 28, 2021, in Marseille, France without the physical presence of its shareholders. All resolutions were voted on in accordance with the Executive Board's recommendations.

A total of 178 votes were cast out of a total of 31,717,812 shares giving right to 32,180,682 voting rights, representing a quorum of 40.141%.

During the meeting, all seven members of the Supervisory Board who were up for election were re-elected. Pascale Boissel's mandate lasts until the AGM in 2022 and Novo Nordisk A/S, represented by Marcus Schindler, M.D., decided not to seek re-election due to Dr. Schindler's new role as Chief Scientific Officer of Novo Nordisk A/S. Novo Nordisk A/S remains a shareholder in the Company but no longer has a seat on its Supervisory Board.

'Novo Nordisk A/S has been a long-standing member of Innate's Supervisory Board, and we thank them for their valued contributions to the Company,' said Hervé Brailly, Ph.D., Chairman of the Supervisory Board.'We wish Dr. Schindler much success in his new role and appreciate his support of Innate.'

The AGM recording, the resolutions, the results of the votes and other documents relating to the AGM are available in the Annual General Meeting 2021 section of the Company's website: https://investors.innate-pharma.com/regulated-information/general-shareholders-meeting

The Company's 2020 20-F is available on the Investors section of the website.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code
Ticker code
Euronext: IPH Nasdaq: IPHA

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'believe,' 'potential,' 'expect' and 'will' and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts, the Company's continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company's business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Tel.: +33 (0)4 30 30 30 30

Innate Pharma
Tracy Rossin (Global/US)
Tel.: +1 240 801 0076

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72


Innate Pharma SA published this content on 28 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2021 20:06:04 UTC.

© Publicnow 2021
All news about INNATE PHARMA
07/16INNATE PHARMA : Corporate Presentation | July 2021
07/06GLOBAL MARKETS LIVE : Facebook, AngloGold, Didi, Weibo, Daimler...
07/06INNATE PHARMA : Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients W..
07/06INNATE PHARMA S A : Trial of Avdoralimab for COVID-19 Did Not Meet Goals; To Sto..
07/06INNATE PHARMA : to Stop Evaluating Antibody for COVID-19 After Mid-Stage Failure
07/06Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pn..
07/06Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID..
07/01INNATE PHARMA : Monthly statement on outstanding equity shares and voting rights
06/22RESULTS PRESENTED AT 16TH INTERNATIO : 00 p.m. CEST / 8:00 a.m. EDT (Form 6-K)
06/22INNATE PHARMA : presents preliminary data from TELLOMAK trial showing clinical r..
More news
Sales 2021 40,8 M 48,3 M 48,3 M
Net income 2021 -45,8 M -54,3 M -54,3 M
Net cash 2021 27,8 M 32,9 M 32,9 M
P/E ratio 2021 -2,48x
Yield 2021 -
Capitalization 215 M 256 M 255 M
EV / Sales 2021 4,60x
EV / Sales 2022 2,74x
Nbr of Employees 244
Free-Float 75,2%
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 2,72 €
Average target price 5,73 €
Spread / Average Target 111%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.230.85%138 784
LONZA GROUP AG21.77%56 806
CELLTRION, INC.-27.16%31 282
SEAGEN INC.-12.38%26 668